Elanco's Credelio Quattro™ Receives FDA Approval for Canine Screwworm Treatment

Elanco Secures FDA Conditional Approval for Credelio Quattro™



Elanco Animal Health has achieved a significant milestone by receiving conditional approval from the U.S. Food and Drug Administration for Credelio Quattro™-CA1, a chewable tablet designed to combat infections of New World screwworm larvae in dogs. This marks a notable advancement in the ongoing battle against a pest that threatens not only canines but various other warm-blooded animals.

What is New World Screwworm?


The New World screwworm is a parasitic fly that primarily affects livestock but can also infest household pets and wildlife. The larvae of this fly feed on the living tissue of their hosts, leading to severe injuries and, if left untreated, potentially fatal complications. In recent years, instances of this pest have been reported alarmingly close to the U.S. border, particularly in relation to cattle movements from Southern regions.

A Broader Spectrum of Treatment Options


Credelio Quattro™-CA1 becomes Elanco's third product aimed at treating New World screwworms, following previous Emergency Use Authorizations for similar products like Credelio™ for dogs and Credelio™ CAT for felines. Now, healthcare providers for animals have a robust arsenal of treatment options to act preemptively in the event of an infestation.

Efficacy of Credelio Quattro™-CA1


The recent approval was substantiated by a study published in 'Parasites Vectors,' where the active ingredient, lotilaner, demonstrated a remarkable 100% efficacy in combating New World screwworm larvae within a span of 24 hours. The FDA's conditional approval process entails that the treatment has shown safety and a pragmatic expectation of effectiveness, although further evidence of its utility will be required.

Comprehensive Parasite Protection


Credelio Quattro™ is not only effective against New World screwworm but also harbors the broadest spectrum of protection available in a single chewable tablet. It offers coverage against various parasites, including ticks, fleas, and other intestinal worms. Therefore, it serves as not only a treatment but a preventive measure for pet owners and veterinary professionals alike.

Elanco’s emphasis on advancement reflects a commitment to animal health and welfare. Dr. Ellen DeBrander, the company’s Executive Vice President of Research and Development, highlighted the importance of ensuring a proactive approach in providing treatment alternatives to veterinarians, animal shelters, and pet owners.

The Path Forward


As Elanco prepares to roll out changed product labeling in 2026, it aims to create awareness about the dangers posed by New World screwworm while emphasizing the need for year-round parasite protection schemes for pets. Veterinarians like Dr. Casey Locklear urge dog owners to be vigilant, particularly when it comes to seemingly minor injuries that could serve as entry points for screwworm larvae. Using products like Credelio Quattro year-round can significantly contribute to minimizing such risks.

In an era where animal health has become increasingly paramount, Elanco is paving the way for future innovations that not only target existing challenges but also anticipate new ones. The focus on developing effective treatments like Credelio Quattro™ demonstrates a dedication to bettering outcomes for both pets and those who care for them.

Conclusion


Elanco’s Credelio Quattro™-CA1 holds promise for maintaining the health and wellbeing of dogs facing the threat of New World screwworm. With multiple treatment options now available, pet owners can feel assured knowing that effective measures are at their disposal. As Elanco continues to innovate in the animal health space, the industry watches closely for what advancements lie ahead.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.